Literature DB >> 2026487

Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.

D D Von Hoff1, S J Green, J A Neidhart, C Fabian, T Budd, J F Boyd, C K Osborne.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026487     DOI: 10.1007/bf00194553

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

1.  Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.

Authors:  E T Creagan; A J Schutt; J N Ingle; J R O'Fallon
Journal:  Cancer Treat Rep       Date:  1983-11

2.  The treatment of acute leukemia with continuous infusion L-Alanosine.

Authors:  J K Weick; B L Tranum; F S Morrison
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.

Authors:  E T Creagan; H J Long; D L Ahmann; S J Green
Journal:  Am J Clin Oncol       Date:  1984-10       Impact factor: 2.339

4.  Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces.

Authors:  Y K Murthy; J E Thiemann; C Coronelli; P Sensi
Journal:  Nature       Date:  1966-09-10       Impact factor: 49.962

5.  A phase II study of alanosine in advanced large bowel carcinoma.

Authors:  J Rubin; V Hineman; C G Moertel; A J Schutt; R G Hahn
Journal:  Am J Clin Oncol       Date:  1983-04       Impact factor: 2.339

  5 in total
  2 in total

Review 1.  Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Authors:  Joseph R Bertino; William R Waud; William B Parker; Martin Lubin
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Authors:  Hedy Lee Kindler; Howard A Burris; Alan B Sandler; Ira Anton Oliff
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.